Sarepta stock faces scrutiny after UBS reiterates buy rating

UBS reiterated its buy rating and $85 price target for Sarepta Therapeutics (SRPT) despite regulatory concerns surrounding its Elevidys treatment following a second reported death, while the stock has fallen over 70% year-to-date. UBS analysts acknowledge potential FDA action to remove Elevidys from the market given internal agency opposition to its initial approval, but note that withdrawing an approved drug is a lengthy process; meanwhile, other firms like H.C. Wainwright and BMO Capital have downgraded SRPT due to safety concerns, while Scotiabank upgraded the stock, suggesting negative events are priced in and highlighting potential future catalysts.

Analysis

Sarepta Therapeutics (SRPT) faces significant headwinds and heightened regulatory risk following a second reported patient death associated with its Duchenne muscular dystrophy treatment, Elevidys, contributing to a stock decline exceeding 70% year-to-date to $19.70 and a market capitalization of $1.98 billion. Despite these severe developments and a moderately negative sentiment (-0.5 for SRPT), UBS reiterated a buy rating and an $85.00 price target. This positive stance is partly based on a consultation with a former FDA reviewer (conducted before the second death was reported) who suggested that the process of withdrawing an approved drug is typically lengthy, even though some FDA officials had opposed Elevidys' initial approval. However, this contrasts sharply with recent actions from other firms: H.C. Wainwright downgraded Sarepta to sell, BMO Capital moved to Market Perform, and Piper Sandler shifted to Neutral, all citing increased risks and safety concerns, with Piper Sandler specifically reducing Elevidys sales forecasts. Conversely, Scotiabank upgraded SRPT to Sector Outperform, suggesting the substantial negative news may already be priced into the stock. The situation is further complicated by a changing regulatory environment, with the current Health and Human Services Department and FDA leadership described as taking "unprecedented actions." Elevidys represents a crucial component of Sarepta’s commercial portfolio and future growth. Financially, while Sarepta maintains strong liquidity with a current ratio of 4.02, it is also experiencing cash burn. The stock’s RSI indicates oversold conditions. Amidst these challenges, Sarepta's investigational gene therapy SRP-9003 received FDA platform technology designation, potentially streamlining future development, and the company is actively working on modifying Elevidys' immunosuppressive regimen.

Key Decisions for Investors

• Investors should closely monitor all FDA communications and decisions regarding Elevidys, as its market status represents a critical binary risk for Sarepta's valuation and future revenue.
• Given the stock's significant year-to-date decline and oversold RSI, opportunistic investors might consider the current valuation, but must weigh this against the substantial regulatory overhang, ongoing cash burn, and the high uncertainty surrounding Elevidys' future.
• The progress of Sarepta's broader pipeline, particularly the rAAVrh74 viral vector platform and SRP-9003, should be carefully evaluated as potential long-term value drivers that could mitigate risks associated with Elevidys.
• Consider the divergent analyst ratings as indicative of the highly polarized outlook for SRPT, warranting a cautious approach and thorough due diligence on the probability of various regulatory outcomes for Elevidys.